(Q38384654)

English

Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review

scientific article published on 17 March 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

1 reference

Europe PubMed Central

Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Dana M Roque

1

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Elena S Ratner

2

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Dan-Arin Silasi

3

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Masoud Azodi

4

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Thomas J Rutherford

5

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Peter E Schwartz

6

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Wendelin K Nelson

7

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Alessandro D Santin

8

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

language of work or name

0 references

publication date

17 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

137

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

392-400

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

History of the FIGO cancer staging system.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.008

7 January 2021

Identifiers

10.1016/J.YGYNO.2015.03.008

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38384654&oldid=1757106354"